Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical
decisions in cancer care, they have limited ability to identify the transcriptional programs that …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with
phenotypic subtypes that drive therapy response and outcome differences. Histologic …

Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains
clinically challenging. Here, we harnessed circulating tumor DNA (ctDNA) to study tumor …

Aberrant DNA methylation has been implicated as a key driver of prostate cancer lineage
plasticity and histologic transformation to neuroendocrine prostate cancer (NEPC). DNA …

Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the
presence of which changes the prognosis and management of metastatic prostate cancer …

Epidemiological data highlight prostate cancer as a significant global health issue, with high
incidence and substantial impact on patients' quality of life. The prevalence of this disease is …

Simple Summary Liquid biopsy (LB), encompassing the analysis of circulating tumor
material in the blood or urine, has emerged as a powerful tool in the management of …

Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …